amorchem header logo close button Menu
arrow leftBack to portfolio

SemaThera Inc.

SemaThera (www.semathera.com) is a biotech company spun out from our SEMA 3A program led by Dr. Mike (Przemyslaw) Sapieha from the Université de Montréal and Maisonneuve-Rosemont Hospital. SemaThera is focusing on the development of novel anti-SEMA 3A therapies for the treatment of several retinopathies, including diabetic macular edema (DME) and the wet form of age-related macular degeneration (wAMD). SemaThera also holds exclusive rights to various SEMA 3A-based technologies, where semaphorin 3A is involved in neo-angiogenesis, senescence and neuronal regeneration. Such technologies may also become tomorrow’s treatments in cancer and neurodegenerative diseases.

Semathera Inc.